From reading the Quarterly reports I got it that a research firm (NSABP)is running the TNBC trial drug combination with Keytruda and Generex is paying that company. I could be wrong but read the first paragraph at the top of 44 of the 10Q filed Dec 21, 20. Generex total cost is about $2.1 mil and they have paid $500k so far. I am thinking NSABP is in control of that trial and Generex can neither slow it down or speed it up. All payments are made by Generex on a milestone basis to NSABP. Patience on that one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.